Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Gilead Sciences Inc

GILD
Current price
78.33 USD +1.04 USD (+1.35%)
Last closed 77.61 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 93 739 597 824 USD
Yield for 12 month -10.97 %
Week
Month
Year
GILD
21.11.2021 - 28.11.2021

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California. Address: 333 Lakeside Drive, Foster City, CA, United States, 94404

Analytics

WallStreet Target Price

89.76 USD

P/E ratio

16.1092

Dividend Yield

3.99 %

Current Year

+27 281 000 000 USD

Last Year

+27 305 000 000 USD

Current Quarter

+7 050 000 000 USD

Last Quarter

+6 599 000 000 USD

Current Year

+21 624 000 000 USD

Last Year

+20 704 000 000 USD

Current Quarter

+5 485 000 000 USD

Last Quarter

+5 157 000 000 USD

Key Figures GILD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 11 738 000 384 USD
Operating Margin TTM 38.51 %
PE Ratio 16.1092
Return On Assets TTM 9.21 %
PEG Ratio 0.5134
Return On Equity TTM 26.92 %
Wall Street Target Price 89.76 USD
Revenue TTM 27 391 000 576 USD
Book Value 17.89 USD
Revenue Per Share TTM 21.9 USD
Dividend Share 2.98 USD
Quarterly Revenue Growth YOY 0.1 %
Dividend Yield 3.99 %
Gross Profit TTM 21 624 000 000 USD
Earnings Share 4.67 USD
Diluted Eps TTM 4.67 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY 21.8 %
Profit Margin 21.45 %

Dividend Analytics GILD

Dividend growth over 5 years

40 %

Continuous growth

7 years

Payout Ratio 5 years average

822 %

Dividend History GILD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 3
Ex Dividend Date 14.12.2023
Forward Annual Dividend Yield 3.99 %
Last Split Factor 2:1
Payout Ratio 42.92 %
Last Split Date 28.01.2013
Dividend Date 28.12.2023

Stock Valuation GILD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 16.1092
Forward PE 10.3842
Enterprise Value Revenue 4.0837
Price Sales TTM 3.4223
Enterprise Value EBITDA 10.4657
Price Book MRQ 4.2011

Financials GILD

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators GILD

For 52 weeks

72.54 USD 86.75 USD
50 Day MA 76.64 USD
Shares Short Prior Month 19 503 923
200 Day MA 78.45 USD
Short Ratio 2.82
Shares Short 18 127 206
Short Percent 1.63 %